Jain Kewal K
Jain PharmaBiotech, Basel, Switzerland.
Adv Protein Chem Struct Biol. 2016;102:41-52. doi: 10.1016/bs.apcsb.2015.09.002. Epub 2015 Nov 11.
Advances in proteomic technologies have made import contribution to the development of personalized medicine by facilitating detection of protein biomarkers, proteomics-based molecular diagnostics, as well as protein biochips and pharmacoproteomics. Application of nanobiotechnology in proteomics, nanoproteomics, has further enhanced applications in personalized medicine. Proteomics-based molecular diagnostics will have an important role in the diagnosis of certain conditions and understanding the pathomechanism of disease. Proteomics will be a good bridge between diagnostics and therapeutics; the integration of these will be important for advancing personalized medicine. Use of proteomic biomarkers and combination of pharmacoproteomics with pharmacogenomics will enable stratification of clinical trials and improve monitoring of patients for development of personalized therapies. Proteomics is an important component of several interacting technologies used for development of personalized medicine, which is depicted graphically. Finally, cancer is a good example of applications of proteomic technologies for personalized management of cancer.
蛋白质组学技术的进步通过促进蛋白质生物标志物的检测、基于蛋白质组学的分子诊断以及蛋白质生物芯片和药物蛋白质组学，为个性化医疗的发展做出了重要贡献。纳米生物技术在蛋白质组学中的应用，即纳米蛋白质组学，进一步增强了在个性化医疗中的应用。基于蛋白质组学的分子诊断在某些疾病的诊断和理解疾病发病机制方面将发挥重要作用。蛋白质组学将成为诊断与治疗之间的良好桥梁；两者的整合对于推进个性化医疗至关重要。使用蛋白质组学生物标志物以及将药物蛋白质组学与药物基因组学相结合，将能够对临床试验进行分层，并改善对患者的监测以开发个性化治疗方案。蛋白质组学是用于开发个性化医疗的几种相互作用技术的重要组成部分，文中以图形方式进行了描述。最后，癌症是蛋白质组学技术在癌症个性化管理中应用的一个很好的例子。
